Avoro Capital Advisors IOBT Position
ExitedAvoro Capital Advisors exited their position in IO Biotech, Inc. (IOBT) in Q4 2023, after holding the stock for 4 quarters.
The position was first reported in Q1 2023 and has been tracked across 4 quarterly 13F filings.
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Full company profile →Short Interest
7.5%
2.1 days to cover
Avoro Capital Advisors IOBT Position History
Frequently Asked Questions
Does Avoro Capital Advisors own IOBT?
No. Avoro Capital Advisors exited their position in IO Biotech, Inc. (IOBT) in Q4 2023. They previously held the stock for 4 quarters.
How many hedge funds own IOBT?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in IOBT.
When did Avoro Capital Advisors first buy IOBT?
Avoro Capital Advisors's position in IOBT was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's IOBT position increasing or decreasing?
Avoro Capital Advisors completely exited their IOBT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IOBTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →